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Objective: The symptomatic treatment of osteoarthritis (OA) remains to be improved, as many patients do
not respond well to current palliative therapies and/or suffer unacceptable adverse events. Given the
unmet need for innovative, effective and well-tolerated therapies, it is important to develop the means to
estimate the ongoing safety proﬁle of novel therapeutic agents over short- and longer term use.
Design: Methods are presented to estimate the number of serious adverse events (SAEs) of interest
considered as “acceptable” per 1000 patient-years exposure and to estimate the numbers of patient-
years needed in a randomized controlled trial (RCT) to meet objectives. As exposure is increased, more
evidence is accrued that the overall risk is within study limits. It is equally important that requirements
for delineating the safety of promising new therapies not create barriers that would preclude their
development. Therefore, ongoing surveillance of occurrence of SAEs of interest during clinical devel-
opment is proposed, for example after every incremental 500 patient-years exposure are accrued.
Results: This paper and others in this special issue focus on identiﬁcation of safety signals for symp-
tomatic treatments of OA. Much less information is available for agents aimed at slowing/preventing
structural progression but it is expected that a higher risk proﬁle might be considered acceptable in the
context of more promising beneﬁt.
Conclusion: This paper provides a proposal and supporting data for a comprehensive approach for
assessing ongoing safety during clinical development of both palliative and disease-modifying therapies
for OA.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a common and heterogeneous disease that
occurs worldwide, predominantly in older individuals60,37,52. The
pain, impairment in physical function, and disability associated
with OA vary greatly from mild and intermittent to severe and
continuous51,50,53, prompting patients to seek a wide variety of
treatments, ranging from intermittent use of analgesics to total
joint arthroplasties, with greatly varying associated risks61,34,32.: Vibeke Strand, Division of
ol of Medicine, Palo Alto, CA,
rand), dbloch@stanford.edu
ff), Paul_peloso@merck.com
s Research Society International. PAs cyclooxygenase-2 selective (COX-2) agents were developed
that decreased the risk of gastrointestinal (GI) bleeding1,45, it
became apparent that both non-selective nonsteroidal anti-
inﬂammatory drugs (nsNSAIDs) and selective COX-2s were asso-
ciated with increased risks for cardiovascular (CV) events43,47,49,25.
Results to date have led to the conclusion that treatment-associated
increases in CV risk vary according to patient characteristics,
underlying risk factors, speciﬁc NSAID/COX-2 administered, and
dose and duration of treatment13,2,56,55,31,25,26. Recognizing that
absolute rates of risk are small and the large number of factors
inﬂuencing NSAID/COX-2-associated increases in CV risk12,31
means that the incidence of treatment-associated CV events
require evaluation, not only in multinational randomized control
trials (RCTs), but also in large post-approval, randomized pragmatic
trials and longitudinal observational studies (LOS)4,28,56. RCTs,
cohort studies and case control series contribute information to the
evolving safety proﬁle of a novel therapeutic, once approved, andublished by Elsevier Ltd. All rights reserved.
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assessment of uncommon serious adverse events (SAEs) relies
upon voluntarily reported events in LOS, this may underestimate
adverse event (AE) frequency and/or be confounded by channeling
bias, other unidentiﬁed comorbidities and risk factors17,40. In the
case of liver toxicity associated with NSAIDs and in particular with
a recent COX-2 selective inhibitor, lumiracoxib, large numbers of
patients needed be studied to characterize this rare risk.
Uncommon and/or less easily predicted complications of OA
treatment (e.g., idiosyncratic skin rashes, including Stevens -
Johnson syndrome and/or Toxic Epidermal Necrolysis)48, those
reﬂective of comorbidities (e.g., hypertension (HTN), diabetes)6,
and/or polypharmacy frequently present in subjects with OA5,44
should also be considered. Recent data and RCTs indicate as many
as 40e50% of OA subjects have HTN; they are twice as likely to
develop a myocardial infarction (MI) and 70% more likely to suffer
a cerebrovascular accident (CVA). In addition there is an associated
increased risk of type II diabetes, with its own attendant CV risks.
Other common comorbidities in the OA population include chronic
obstructive pulmonary disease (COPD), peptic ulcer and other GI
diseases, increased risk of obesity and metabolic syndrome and
increased incidence of CV disease with increasing age, impairment
in renal function and osteoporosis11,58,59. Thus, it is important that
novel therapies under development include drugedrug interaction
studies in this patient population as well as information regarding
instability in blood pressure, blood glucose, and/or renal function
during RCTs e and that CV events be carefully surveilled.
A question posed by the U.S. Food and Drug Administration
(FDA) in 2007 regarding the Draft 1999 Guidance Document for
development of novel agents for treatment of OAwas “What should
the size and duration of exposure of the safety database be for
agents offering symptomatic relief?”18. This paper outlines
recommendations for ongoing evaluation of the safety of novel
agents for symptomatic treatment of OA. Other therapies, including
topical or intra-articular agents that do not result in signiﬁcant
systemic drug exposure are not considered. In addition, pure
analgesics without anti-inﬂammatory effects are not addressed.
Simple analgesics, over-the-counter (OTC) acetaminophen and oral
opioid drugs, have signiﬁcant well-recognized safety risks, and are
not included in this discussion46,42,41,10.
Recommendations provided address studies of novel agents and
it is acknowledged that the known safety proﬁle for any new
therapy will almost certainly evolve after approval and subsequent
administration to thousands and millions of patients rather than
the limited numbers typically involved in a clinical development
program, also including those with comorbidities that would
otherwise preclude their participation in pre-approval RCTs. The
following discussion is also undertaken with the assumption that
any newmolecular entity in development for symptomatic relief of
OA should have no evidence of risks beyond those identiﬁed with
currently approved therapies since these agents are palliative in
nature and do not alter the natural history of the disease. An
acceptable safety proﬁle for a disease-modifying agent may also be
very different than that for a symptomatic therapy and a certain
degree of greater risk may be acceptable for achievement of thisTable I
Size of safety databases
Osteoarthritis efﬁcacy studies and ICH guidelines (estimated summation)
DMARD approvals in RA (disease-modifying anti-rheumatic drugs: synthetics: 1998;
DM CV risk guidance for approval (based upon RR 95% upper CI <1.8)
DM CV risk guidance safety study (based upon RR 95% upper CI <1.3)
OA CV outcome studies (TARGET, MEDAL, PRECISION studies)beneﬁt57. The magnitude of beneﬁt with a novel palliative therapy
for OA should be an important determinant of the number of
patients required to demonstrate an acceptable understanding of
its associated risk.
Current guidances
Safety databases vary according to size and populations studied,
whether pre- or post-approval, by recognized risks, and class of
therapeutic agent (Table I). Depending upon an a priori concern
regarding SAEs based upon nonclinical information or results from
early trials, larger studiesmay be required to better characterize the
safety proﬁle of a new therapy. As it is difﬁcult to predict the safety
proﬁle of a novel agent and accurately determine the 95% conﬁ-
dence intervals (CIs) around the incidence of uncommon to rare
SAEs, it is recommended that ongoing estimates of risks during
clinical development be performed to inform decisions regarding
the size of the database required for approval.
The previous 1999 FDA OA Draft Guidance Document did not
speciﬁcally address safety recommendations19 and International
Conference on Harmonization (ICH) recommendations published
in 199433 were generally applied for development of novel agents
that would be used both intermittently and regularly on a chronic
basis. The ICH guidelines recommend 1500 patients as the
minimumnumber of subjects to have received a new therapeutic at
any dose for any time period; 300e600 patients be treated for
6months and aminimum of 100 patients for at least one year at the
proposed dose.
With identiﬁcation of relatively rare SAEs of variable incidence,
the evaluation of risk based upon exposure (e.g., number of events
per 100 patient-years) has become important. For example, clinical
development programs with 3-month RCTs in OA aimed at
assessing symptomatic relief typically have resulted in databases
with approximately 1000 patient-years of exposure. As noted
above, these limited databases may not permit identiﬁcation of rare
but likely important SAEs. For example, early biologic inhibitors of
tumor necrosis factor (TNFa) for treatment of rheumatoid arthritis
(RA) were approved with limited databases, and post-marketing
surveillance was required to identify uncommon SAEs such as
opportunistic infections, lymphomas and malignances38,27. Post-
approval recognition of these SAEs motivated the requirement for
2500 patient-years of exposure for approval of subsequent new
disease-modifying anti-rheumatic drugs (DMARDs) for treatment
of RA22e24.
Similarly, FDA has recently issued two guidances for evaluation
of new agents for treatment of diabetes mellitus (DM), recom-
mending a minimum of 3000 patient-years of exposure20 and
based on recognition of increased CV risk in subjects with Type 2
DM, 5000 patient-years of exposure21.
Requirements for safety assessments are based upon point
estimates of relative risk and the 95% CIs estimated around that
risk. In the past relatively rare risks were better deﬁned and 95% CIs
narrowed by performance of large post-marketing safety trials
conducted with the goal of increasing exposure byw5000 patient-
years and/or by studies which included subjects with morePatient-years exposure
(approximate)
1000
biologic agents: 2002) 2500
3000
5000
10,000e30,000
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Based on “signals” identiﬁed during clinical development, such
post-approval studies are requested on a more frequent basis. The
recent guidance from the FDA regarding CV risk assessment for new
therapies in Type 2 DM provides insight into why such recom-
mendations have been issued.
The current guidance to assess pre-approval CV risk of therapies
for Type II DMproposes that the upper limit of the 95% two-sided CI
of the risk ratio relative to control must be <1.8 and the absolute
risk ratio <1.5, representing a nominally signiﬁcant increase. A risk
ratio <1.3 may not require a post-marketing safety trial and those
intermediate between 1.3 and <1.8 will require a clearly demon-
strated positive beneﬁt/risk ratio to support approval. Some
scenarios of numbers of patient-years of exposure accrued that are
unlikely to meet risk criteria are illustrated in Fig. 1, based on
identiﬁcation of major adverse cardiac events (MACEs) of CV death,
fatal or non-fatal MI or CVA. Increasing numbers of patient-years of
follow-up are required to be included in RCTs to identify SAEs with
sufﬁcient power (say 80%), especially if the predetermined inci-
dence of SAEs of interest is rare and if the aim is to exclude risk
ratios <1.8 with the incidence of interest equal to 2%, Fig. 1 shows
the power is approximately 78% with 3000 treated and 2000
control patient-years of follow-up; if the incidence is 1%, then the
power is approximately 83% with 7000 treated and 4000 control
patient-years of follow-up. Clearly this poses a challenge as CV
event rates in RCTs are generally 1% and do not approach 2%
except in particularly high-risk populations. Similarly, event rates
are lower in subjects with newly diagnosed or earlier disease, with
fewer comorbidities; recognizing also that high-risk patients are
generally excluded from RCTs early in clinical development.
In Appendix 1 a formula is presented to statistically estimate the
number of patient-years of follow-up needed in RCTs to meet these
objectives. For example, if approximately 14,800 treated patients-
years and 7400 control patient-years have been accrued with an
SAE rate of 0.5%, then the power to exclude a rate ratio of 1.8 is 80%.
Effective implementation of a guidance requiring absolute risk be
determined as <1.3e1.5 will be challenging, likely increasing clin-
ical development times by 1e3 years and a minimum of $150e300
million in costs. Clearly these cost implications will limit the
incentives for identifying and proving new therapies.
Symptomatic treatment of OA
Symptomatic agents for the treatment of OA are administered
to large numbers of patients in a primary care setting15. TypicallyFig. 1. Patient Exposure Recommendations from DM. Guidance Unlikely to Meet CV Risk Cr
MACEs based on 3000 e 7000 patient-years exposure of the new therapy vs 2000 e 4000they are systemically active and may interact pharmacokinetically
and/or pharmacodynamically with other therapies/drug classes
and non-pharmaceutical agents (e.g., herbal remedies)8,14. Thus,
the safety of oral treatments for OA must be carefully charac-
terized in multiple settings with chronic intermittent and daily
use.
Risk assessments for newly approved agents in a given thera-
peutic class continue to change over time following introduction of
the ﬁrst products into the clinic to identiﬁcation of SAEs with new
members of the class still in clinical development. The probability
of identifying rare SAEs, typically identiﬁed via the Adverse Event
Reporting System, increases with long-term exposure of larger
numbers of patients with more diverse demographic and clinical
characteristics than those enrolled in RCTs4.
Based upon the above discussion, the following is proposed for
assessment of novel therapies for OA. Minimum requirements by
ICH guidelines require a database of 2500e3000 patients followed
for one year if the SAE incidence rate is 0.1% (Table II).
A database of 2500e3000 patient-years will detect at least one
SAE with high certainty if the incidence rate is of 0.1%. A standard
phase 3 program, which meets current FDA requirements, has
approximately 50%75% power to exclude a hazard ratio of 1.8 in
terms of CV events, assuming a 1%e2% rate in the study population
(Fig. 1). Assuming that the observed event rate in such a phase 3
program is approximately 1%, additional clinical work will be
necessary to better deﬁne the overall risk. To increase power,
options could include either increasing exposure and number of
patients in the pivotal trials or conducting a separate safety study
(initiated prior to submission but likely not completed before
approval). At present, a CV outcomes trial would likely require
>20,000e30,000 patients treated for at least 3 years, akin to that
planned in OA by the PRECISION (Prospective Randomized Evalu-
ation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen)
study3.
Predicated on the above guidance for the diabetic population, it
is possible to extrapolate this requirement to patients with OA, who
are usually older but with similar comorbidities and overall 10-year
risk for development of coronary heart disease36,16,39. It is possible
to develop a statistical estimate of the number of SAEs of interest
considered as “acceptable” per a chosen number of patient-years
exposure. As an example, for an SAE rate of 1/1000 patient-years,
one can calculate that after 3065 patient-years of exposure, there
should be nomore than 6 SAEs, or the estimated lower limit of a the
95% CI of the true SAE rate exceeds 1/1000 patient-years. (see
Appendix 1)iteria. Power to exclude a Hazard Ratio or Risk Ratio of 1.8 or 1.3 based on SAEs of
of an active control with incidence of adverse events between 0.25 to 2%.
Table II
ICH estimates for study duration, exposure, and characterization of AE incidence
rates (ICH, 1994)
Duration Time Exposure
(patients)
Incidence Rate
characterized
Short-term 3 months 1500 w1%
Mid term 6 months 300e600 0.5e5%
Long-term 1 year 100 3%
Not ICH characterized 1 year 2500e3000 0.1%
ICH guidelines (E1, 1994) are considered “minimums” to characterize the safety of
a new agent, but:
 Don’t reveal rare (<1/1000) or long-ter AEs nor,
 AEs in at risk or special populations (for example those with HTN, on low-dose
aspirin or other concomitant medications)
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years are accumulated throughout the clinical development
program. Hence, one could propose that once an SAE of interest was
identiﬁed, the number accrued as each RCT is completed could be
calculated. As exposure is increased the 95% CIs around the risk
would narrow, and either lend more or less conﬁdence to the
estimate that the overall risk remains within the predeﬁned
acceptable rate, for example <1/1000. These assumptions permit
establishment of CI’s for actual SAE rates, to decide if they violate
the predeﬁned “acceptable rate”. For the example, after 1000
patient-years of follow-up one expects 10 such SAEs, but as many as
15 SAEs could occur before establishing with 95% certainty that the
true rate exceeds the predeﬁned rate. Once 3000 patient-years
have been accrued, as many as 39 SAEs could occur before estab-
lishing with 95% certainty that the true rate exceeds the predeﬁned
rate. The example in Appendix 1 illustrates how a proposal could be
pre-speciﬁed that after every incremental 500 patient-years
exposure are accrued, the number of observed SAEs of interest
would be compared to the allowable limit to determine if the SAE
rate is in danger of violating the “acceptable” rate. This requires an
ongoing surveillance of the occurrence of SAEs of interest in the
clinical development program, but may preclude the need for large
expensive post-marketing surveillance studies.
Statistically, this same metric can be applied to patient pop-
ulations in post-marketing surveillance. Practically, this requires an
agreement regarding an estimate of patient-years and conﬁdence
that all SAEs are reported and adjudicated. More realistically, this
metric for RCTs can be applied to LOS to monitor SAEs of interest
after more patient-years of follow-up are accrued, as in current
registries for RA and other health provider databases. Critical
considerations include the deﬁnition of SAEs of interest, such as
MACEs as well as the deﬁnition of an “acceptable” SAE rate per 100Table III
CV risk estimates from various databases for selected NSAIDs
Drug Database CV risk or hazard rate (95% CI)
Celecoxib RCTs 1.10 (0.70e1.60)
1.30 (0.60e2.60)
2.30 (0.90e5.50)
Cohort studies 1.32 (0.69e2.16)
Case control series 1.01 (0.90e1.13)
Naproxen RCTs 1.57 (0.87e2.61)
Cohort studies 0.94 (0.85e1.04)
Case control series 0.96 (0.84e1.10)
Ibuprofen RCTs 1.18 (0.93e1.19)
Cohort studies 1.12 (0.90e1.38)
Case control series 1.06 (0.95e1.18)
Diclofenac RCTs 1.05 (0.93e1.19)
Cohort studies 1.36 (0.51e3.65)
Case control series 1.36 (1.21e1.54)
Strand Lancet 2007 [McGettigan et al. summarized with permission and Solomon,
et al. updated for Lancet 2007 publication]patient-years exposure and the power available to rule out exces-
sive rate ratios. As an example, Table III presents CV risk estimates
based on RCTs, cohort studies and case control series with selected
NSAIDs.
Post-marketing commitments for RCTs and/or observational
studies should be focused upon patient populations likely to be at
higher risk for uncommon AEs and, therefore, not frequently
studied in sufﬁcient numbers prior to approval to estimate such
risk. There should be a commitment to collect safety information
after approval to narrow the “window” of CI estimates around
actual risks (known or unknown) to <1:10,000e1:30,000. To ach-
ieve this, RCTs and other means (e.g., claims databases) should be
used. The present recommendations also take the position that an
outcomes study prior to registration should not be required if the
SAE rate of interest remains low and within the acceptable pre-
deﬁned limits.
Remaining questions
There are a number of questions that remain to be addressed
regarding the safety of OA treatment. The most important of these
include:
 Do the comorbidities in OA require considerations similar to
those in diabetic populations?
 What approach to safety analysis do we employ for non-
systemically absorbed, topical and/or intra-articular-
administered products?
 How should we assess safety for potentially structure-
modifying and/or “preventive” agents?
 How do we strike a “reasonable balance” between potential
risk and promising beneﬁt?
 What would be the impact on sample size calculations of
identiﬁed genetic polymorphisms potentially affecting both
safety and efﬁcacy?
 In this regards, what role might population pharmacokinetics
play?
 If we can enrich enrolled patient populations for extreme
examples of the above (e.g., extensive and poor metabolizers
and/or patients expressing higher vs lower levels of target
receptor), how might we reduce sample sizes?
Expensive large scale RCTs may not answer the appropriate
questions, due to types of patients accrued and well-recognized
confounders such as dropouts and appropriate comparator agents,
as well as the duration needed to generate sufﬁcient data. It is
hoped that this proposal offers a ﬂexible approach to assess the
safety of a promising novel therapy in OA that is also pragmatic.
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Appendix 1. Statistical methodology
Let ti denote the person-years of observation of the i-th patient
in a cohort of N patients followed within the interval of time [0, T],
and M ¼ Pn1 ti denote the number of patient-years of observation
of the entire cohort. During the follow-up period each patient
either does or does not have the serious adverse event (SAE) of
interest.
Let di ¼ 1 if the i-thpatienthasa serious adverseeventand di ¼ 0
if the patient does not have a serious adverse event.
Let K represent the random variable for the number of SAEs and
let k ¼ PN1 di; that is, k¼ number of events observed in the interval
[0, T].
Assume that K is distributed as a Poisson random variable with
mean and variance equal to the theoretical rate (l) that we wish to
estimate, multiplied by M. Thus
Probability ðK ¼ kÞ ¼ elMðlMÞk1
k!
(1)
The mean (“expected value”) and variance of K are both equal
lM. The rate estimator is given by K/M, which is estimated by k/M.
The variable K/M is approximately normally distributed and
a conﬁdence interval for the rate is more accurately estimated by
natural logarithmic transformation. The lower and upper one-
tailed bounds of the 95% CI of ln (K/M) are estimated by
lnðk=MÞ  1:645=
ﬃﬃﬃ
k
p
lnðk=MÞ þ 1:645=
ﬃﬃﬃ
k
p (2)Should two-sided intervals be required, then replace 1.645 by
1.96 in the equation (2) expressions.Number of SAEs allowed for a given number of patient-years of
follow-up
By taking the exponential of the above interval one obtains the
lower bound of the 95% CI for the rate itself,
k
M
e1:645=
ﬃﬃ
k
p
(3)
Let L¼minimum total number of patient-years of follow-up that
the study subjects could have accrued by time T, at which time k
SAEs have occurred, to establish with 95% conﬁdence that the true
rate does not exceed “Y/1000” patient follow-up years. The choice
of “Y” is pre-speciﬁed; for example, if Y¼ 1, then the rate is 1/1000
years of follow-up, or 0.1% per year of follow-up. Formula (3) above
is the one used to derive numerical results. This is done in two steps
as follows:
(i) Set
k
L
e1:645=
ﬃﬃ
k
p
¼ Y=1000
(ii) For a ﬁxed number of SAEs (k), solve equation (i) for L
Example 1: If Y¼ 1 and k¼ 6,
L ¼ ke
1:645=
ﬃﬃ
k
p
Y=1000
¼ 6
1=1000
e1:645=
ﬃﬃ
6
p
¼ 6ð0:5109Þð1000Þ=1
¼ 3065:4 years:
This would be rounded up to L¼ 3066 years. In words, if there
are least 3066 years of patient follow-up at which time at most 6
patients have been identiﬁed as having had the SAE, then the
Investigator can be assured (with 95% conﬁdence) that the
evidence at that time does not support a conclusion that the true
SAE rate exceeds 1/1000 patient-years of follow-up. However, if
either 6 SAEs have occurred before 3066 patient-years have been
accrued or if 7 SAEs have occurred in the ﬁrst 3066 years of follow-
up, then there is 95% conﬁdence that the true rate exceeds 1/1000
patient-years of follow-up.
Example 2: How a proposal could be pre-speciﬁed during drug
development that after every incremental 500 patient-years of
exposure are accrued, the number of observed SAEs of interest
would be compared to the allowable limit, to determine if, with 95%
conﬁdence, the SAE rate is in danger of violating a pre-registration
“acceptable” rate. The SAE rate of interest chosen for this example
equals 1% (10/1000 patient-years of follow-up).Calculating the number of patient-years of observation for
a controlled clinical trial comparing SAEs with a rate ratio
Assume the two groups to be compared are a treatment group
followed for MT patient-years and a control group followed for MC
patient-years in the ratio r¼MC/MT and the number of SAEs after
MT (orMC) patient-years of follow-up is Poisson distributed; that is,
with mean and variance equal to the theoretical rate lT (or lC)
multiplied by MT (or MC), as represented by equation (1) above.
Assume kT and kC are the observed numbers of SAEs observed in the
treatment group and control group, respectively. The aim is to
demonstrate that the true ratio, R¼ lT/lC is not greater than a pre-
speciﬁed amount, RU say.
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RU and H1 : lT=lC < RU . The estimates of lT and lC are denoted by
l^T ¼ kT=MT and l^C ¼ kC=MC . The null hypothesis is rejected in
favor of the alternative hypothesis if l^T  l^C RU is “small enough.”
If the alternative hypothesis is true, assume lT¼ lC¼ l, so that
R¼ 1. In what follows we present formulas forMT andMC assuming
the hypotheses are tested at the a-level of statistical signiﬁcance
with power¼ (1-b). Using themethods presented byMiettinen and
Nurminen (Reference: Miettinen O and NurminenM. “Comparative
analysis of two rates.” Statistics in Medicine 1985;4:213e226) and
by Laster and Johnson (Reference: Laster LL and Johnson MF.
“Non-inferiority trials: the ‘at least as good as’ criterion.” Statistics
in Medicine 2003;22:187e200), denote the null and alternative
variances of l^T  l^C RU by V0 and V1, respectively.
V1 ¼ lð 1MT þ
R2U
MC
Þ and V0 ¼ lTMT þ
lC
MC
R2U where lT and lC are
maximum likelihood estimators of lT and lC under the null
hypothesis restriction lT=lC ¼ RU . The restricted maximum like-
lihood estimators are lC ¼ lð1þ rÞ=ðRU þ rÞ and lT ¼ lCRU . Then
MT ¼

Za
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
lT þ lC

R2U=r
r
þ Zb
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
l
h
1þ

R2U=r
ir 2
l2ð1 RUÞ2
(4)
and
MC ¼ rMT (5)
where Zu is the upper u-th percentile of the Standard Normal
distribution.
Example 1. A trial has accrued 5000 patient-years of follow-up in
the treatment group (MT¼ 5000) and 3000patients-years of follow-
up in the control group (MC¼ 3000). The predetermined SAE rate of
interest is 1%, expected to be equal in both groups (l¼ 0.01). Choose
1.8 as the upper limit of the rate ratio (RU¼ 1.8) that is of interest to
exclude at the 5% 2-tailed signiﬁcance level (Za¼ 1.96). Then r¼MC/
MT¼ 0.6, lC ¼ 0.0067 and lT ¼ 0.012. Solving equation (4) for Zb
gives Zb¼ 0.54. Referring to the cumulative Standard Normal
distribution, power¼ 70.5%. This is in close agreement with the
power presented for this approximate scenario in Fig. 1.
Example 2. The aim is to design a post-registration study with
80%power (Zb ¼ 0.84) at the5%2-tailed signiﬁcance level (Za¼ 1.96)
to rule out a rate ratio of 1.8 or larger (RU¼ 1.8) where the pre-
determined SAE rate of interest is 0.5%, expected to be equal in both
groups (l¼ 0.005). Assume twice as many patients will be treated
than controls, so r¼ 0.5. Then lC ¼ 0.0033 and lT ¼ 0.0059. From
equations (4) and (5), MT¼ 14,775 patient-years and MC¼ 7388
patient-years. As presented in Fig. 1, if approximately 7000 treated
patients-years and 4000 control patient-years have been accrued
with the predetermined SAE rate of interest equal to 0.5%, then the
power to exclude the rate ratio of 1.8 is approximately 56%.
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